Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Emulation of the SOUL Diabetes Trial in Healthcare Claims
- Conditions
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 43650
- Registration Number
- NCT06659718
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS
- Conditions
- Interventions
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06587698
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Anti-Diabetic Medications to Fight PD and LBD
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT06263673
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 730
- Registration Number
- NCT06246799
- Locations
- 🇺🇸
University Health System Texas Diabetic Institute, San Antonio, Texas, United States
To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 240
- Registration Number
- NCT06147518
- Locations
- 🇮🇳
Dr Rakesh Kumar Jagdish, New Delhi, Delhi, India
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT06054815
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸Velocity Clinical Research, Panorama City, Panorama City, California, United States
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Indiana University
- Registration Number
- NCT05895201
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 20
- Registration Number
- NCT05725798
- Locations
- 🇩🇪
University Hospital Münster, Münster, North Rhine-Westphalia, Germany
Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05667220
- Locations
- 🇨🇳
Beijing Chao-yang Hospital, Capital Medical University, Beijing, Beijing, China
Non-alcoholic Fatty Liver Disease and Its Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT05480007
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.